This study is intended to assess the safety, tolerability and evidence of pharmacodynamic activity of a single intravitreal (IVT) injection of UBX1325 in patients with diabetic macular edema (DME)
This is a Phase 2a Proof-of-Concept (POC) study. The study will enroll approximately 62 patients randomized 1:1 into either the UBX1325 or sham study arms, in order to assess the primary objective. All patients will be followed for approximately 24 weeks.
|Condition||Diabetic Macular Edema|
|Clinical Study Identifier||NCT04857996|
|Sponsor||Unity Biotechnology, Inc.|
|Last Modified on||16 August 2021|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
No annotations made yet
Congrats! You have your own personal workspace now.